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Part A. Literature review 
Introduction 
Myocardial ischaemia occurs when there is interruption to the blood flow in a coronary 
vessel. This results in cardiac muscle cell (myocyte) injury due to the resulting inadequate 
oxygen supply. If ischaemia continues without restoration of blood flow, a myocardial 
infarction (MI) may result.  An MI is marked by irreversible death of cardiac myocytes and 
subsequent impairment of cardiac function, and possibly death (1).  Troponin testing has 
become the reference standard for defining an MI according to the third definition of MI: 
“The term Acute Myocardial Infarction (AMI) should be used when there is acute myocardial 
injury with clinical evidence of acute myocardial ischemia and with detection of a rise and / 
or fall of cardiac troponin values with at least one value above the 99th percentile upper 
reference limit and at least one of the following: symptoms of myocardial ischaemia, new 
ischaemic ECG changes, development of pathological Q waves, imaging evidence of new loss 
of viable myocardium… …or identification of a coronary thrombus by angiography or 
autopsy” (2). 
Ischaemic heart disease, once fairly uncommon within Africa, has rapidly grown as a 
pathology throughout the continent alongside industrialisation and urbanisation (3). 
However, it is unclear whether the diagnostic ability to accurately identify MI grew alongside 
it (4).  In resource limited settings (such as those found throughout Africa), the quality of a 
troponin assay may vary as much its availability (5).  Therefore, as a scarce resource, it is 
important that troponin testing be used judiciously. 
 
Aim 
The aim of this review is to introduce and describe the indications for troponin testing, how 
troponin tests are used, and the interpretation of the findings (specifically where MI is not 
suspected) within the global and local African and South African context. 
 
Objectives of the Literature Review 
1. To provide a brief description of acute coronary syndrome (definition, presentation and 
diagnosis) 
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2. To describe the indications for the use of a troponin test 
3. To describe the use of troponin in the hospital 
4. To describe the interpretation of troponin results 
5. To briefly describe the relevance of these objectives within the South African context 
 
Literature search strategy, including inclusion and exclusion criteria 
The Health Sciences Library was used to perform searches and to obtain the original articles 
reviewed in this study. PubMed and Google Scholar were used to perform additional 
searches using the terms “troponin”, “clinical decision rules”, “HEART score”, “emergency 
department/ centre/ unit”, “accuracy”, “rule out”, “acute cardiac syndrome”. The terms 
“risks”, “indications”, “low resource”, “Africa”, “South Africa” and “Western Cape” were 
added to the Boolean search terms to focus on specific areas of research.  A snowball strategy 
was then used, whereby prominent articles cited in the papers obtained from the index 
search were also accessed and included in the review. 
Inclusion criteria: 
 Publication date: January 2008 - June 2018, 
 Language: English, including studies translated and published, 
 Relevance to topic of study 
Exclusion criteria:  
 Studies outside of the stipulated timeframe,  
 Language other than English,  
 Articles with restricted access 
 
Quality criteria 
Titles and abstracts were initially screened for relevance to the review and those deemed to 
have low relevance or poor external validity were excluded. High-quality evidence, including 
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systematic reviews, was sought to address the aim and objectives. Papers were informally 
appraised against a checklist from the Oxford Centre for Evidence-Based Medicine.  A 
representation in tabular form of appraised papers is not required for a narrative review and 
therefore was omitted. Very little data were available that directly addressed some parts of 
the aim and objectives – particularly with regards to the current practice of troponin use in 
low- and middle-income settings and South Africa – and thus criteria were applied less 
stringently here.  
 
Description of Acute Coronary Syndrome: 
“Acute coronary syndrome is a term used to describe a range of conditions associated with 
sudden, reduced blood flow to the heart. One condition under the umbrella of acute 
coronary syndrome is myocardial infarction (heart attack) — when cell death results in 
damaged or destroyed heart tissue. Even when acute coronary syndrome causes no cell 
death, the reduced blood flow alters heart function and indicates a high risk of heart attack. 
Acute coronary syndrome often causes severe chest pain or discomfort. It is a medical 
emergency that requires prompt diagnosis and care. Treatment goals include improving 
blood flow, treating complications and preventing future problems.” (6) 
 
Presentation of Acute Coronary Syndrome 
Acute Coronary Syndrome may often present with signs such as sweating, agitation, 
vomiting, tachypnoea, pale, cool skin, additional heart sounds or hypotension. Symptoms 
may include a sensation of shortness of breath, nausea, fatigue and pain or pressure in the 
thorax, specifically retrosternal, that can radiate to either side of the neck, jaw, arms, or 
shoulders. (7) Certain signs and symptoms may be grouped into what physicians may call 
‘typical’ for acute coronary syndrome, including nausea, diaphoresis, retrosternal pressing 
chest pain, with radiation into the left side of the neck, jaw or arm. (8) In contrast, ‘atypical’ 
signs and symptoms may include fatigue only, dyspnoea only, delirium, right sided chest pain, 
with radiation into the right arm or side of the neck, stabbing chest pain, epigastric pain or 
positional or pleuritic chest pain. (9) 
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Diagnosis of Acute Coronary Syndrome: 
Physicians typically describe their patient’s history, presentation and physical examination 
uniformly, however, it has been shown by Body et al, in their prospective study, that typical 
signs and symptoms and atypical signs and symptoms do not persistently correlate with 
predicting the presence of ischaemia. For example, patients with left sided chest pain were 
less likely to have a proven infarct than patients with right sided chest pain. (10) Furthermore, 
their findings suggest that the utilisation of clinical signs and symptoms only, may miss an 
unacceptable number of patients with an MI, especially with regards to the timeous 
identification of Acute Coronary Syndrome (ACS) in the context of acute chest pain. This 
suggests that neither typical nor atypical clinical features are reliable as a sole indicator of 
the presence of cardiac ischaemia. Further investigations are thus required, in an effort to 
determine effective, but also affordable alternate methods of ACS identification. 
Cervellin and Rastelli (2016), indicate that clinical gestalt does well to predict the presence 
of an ischemic event, in patients presenting with typical or atypical clinical signs. However, 
it does especially well when used in conjunction with a suggestive electrocardiogram (ECG), 
which is elaborated upon below. (11)  
 
The electrocardiogram or ECG 
Acute Coronary syndrome, as described earlier, encompasses a range of diagnoses – each 
with its own ECG features. These include ST elevation myocardial infarction (STEMI), Non-ST 
Elevation myocardial infarction (NSTEMI) and Unstable Angina (UA). STEMI is defined by the 
presence of an elevation of the ST segment of the ECG, corresponding to a region of the 
heart, with reciprocal ST depression in the opposite leads. NSTEMI presents with ST 
depression and UA may present with non-specific changes. In order to distinguish between 
these and in order to clarify the need for thrombolysis – specific biomarkers are used to 
diagnose the presence of infarcted myocardium. (12) 
 
Cardiac Biomarkers 
Since the first use of biomarkers in assisting with identification of myocardial ischaemia, 
there have been a number of different types used and studied. Over the years, these 
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included creatine kinase –muscle/brain (CK-MB), cardiac myoglobin, B-type natriuretic 
peptide (BNP), the troponins and other more obscure markers.  The introduction and use of 
these cardiac biomarkers improved the correct identification of cardiac ischaemia. Cardiac 
biomarkers are typically enzymes which may be present in elevated levels in the patient’s 
serum in the presence of cardiac myocyte injury, resulting, for example, in the leaking of 
enzyme from the myocyte. (13) CK-MB, cardiac myoglobin and BNP will be discussed briefly 
below.  Troponin will be discussed separately. 
 
Creatine Kinase Muscle/Brain (CKMB) 
CKMB is an enzyme that is released by muscle cells in the body when they undergo cell death. 
It is useful, because acute cardiac cell death will cause a predictable rise in the level of CKMB, 
and correlates well with the extent of the infarct. The problem with CKMB is that other 
causes of non-cardiac muscle death, such as trauma, may also cause a rise above the normal 
limit, causing a false positive test. To help clarify the source of the CKMB rise, clinicians may 
repeat the test and observe a significant rise in levels over time, but this is both time-
consuming and resource intensive. (14) 
 
Cardiac Myoglobin 
Myoglobin is a haem protein present in skeletal and cardiac muscle and was initially of 
interest due to its rapid rise (2-4 hours, compared to 4-6 for CKMB), a result of its low 
molecular weight. Similar problems exist, however – the protein may rise in the presence of 
other causes of skeletal muscle damage, obfuscating the clinical picture. (15) 
 
B-type natriuretic Peptide 
BNP is a hormone released by cardiac myocytes in the presence of left ventricular 
dysfunction and has been shown to increase predictably in the presence of infarction. The 
hormone is not specific, however, and may also be elevated in the presence of long-standing 
heart failure and renal impairment. (16) 
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Troponin 
Troponins are regulatory proteins that are involved in the calcium mediated interaction 
between actin and myosin in cardiac myocytes. Troponin I and T have been found to be 
superior to other biomarkers in terms of sensitivity, though Troponin T may appear in very 
small amounts in skeletal muscle cells. Troponins are commonly used in conjunction with 
clinical history and examination and ECG findings in order to make definitive treatment 
decisions. (17) Unfortunately, Troponin’s specificity may be compromised by the fact that 
various other causes of cardiac myocyte ischaemia can cause elevated levels.  
 
Indications for the use of Troponin Testing 
Troponin is a protein present in cardiac and skeletal muscle that plays a role in muscle 
contraction. (18) Troponin I, a subunit of Troponin, is present only in myocardium. (13) During 
damage to myocytes, such as myocardial infarction, Troponin I is released into the blood – 
and can be used as a marker of cardiac cell death. (19) This distinction allows the clinician to 
distinguish between infarction and angina, in a patient with chest pain, which has led to its 
implementation in the diagnosis of MI. (20)  
In general, the sensitivity of Troponin I is estimated at >99% if taken between 3-6 hours from 
onset of injury, while the specificity is estimated at 80-85%. (21, 22) This means that the test 
has a high likelihood of detecting cardiac myocyte damage, but that other conditions may 
cause the result to be elevated. (22) Its high sensitivity also allows myocardial damage to be 
excluded with confidence if negative. (23)  
The release of Troponin takes place during any form of myocyte damage – this means that 
the protein will be present in patients who have sustained cardiac muscle damage by other 
means. (24) This includes chronic cardiac causes of myocyte damage, such as in heart failure, 
arrhythmias, and inflammatory conditions such as myocarditis or pericarditis, 
cardiomyopathies or traumatic cardiac injury, such as contusion. (25) Non-cardiac conditions, 
which cause cardiac myocyte damage by indirect means, can also cause raised Troponin I 
levels – such as sepsis, kidney disease, aortic aneurysm, COPD or central nervous system 
disorders such as subarachnoid haemorrhage. (20, 26, 27) Certain drugs and toxins may have 
the same effect. As such, there are a multitude of reasons why Troponin I results need to be 
interpreted in the context of clinical history, physical examination and the electrocardiogram 
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(ECG). (28) Serial testing which reveals a significant increase in Troponin I levels over time is 
the best indicator of the presence of infarction. (29) 
 
History of Troponin use in Hospitals 
In 1997, Mair suggested that other biomarkers should no longer be used and that attention 
of clinicians should be focused on the Troponin markers, which seemed superior in both 
sensitivity and specificity. (13) This was supported by Thygesen et al (2012), whose report 
indicated high sensitivity with the use of Troponins, specifically in the acute care setting, 
while Wu et al, stated that: “…use of a highly sensitive assay produces a higher clinical 
sensitivity for AMI patients compared to an assay with conventional analytical sensitivity.” 
(19, 30) 
The use of Troponin I as point of care tests underwent critical review by Bingisser et al. in 
2012 and Keller et al (2011) showed that using specifically Troponin I as an early marker of 
myocardial ischaemia improved diagnostic yield. (22, 31) This is supported by further studies 
by Kaess et al (2017), Lewandrowski et al (2014) and also in a systematic review by Westwood 
et al (2015). (27, 32, 33) Conversely, Troponin I is also able to rule out the presence of an 
ischemic event by way of its absence when used in the appropriate time frame. (22)  
Bingisser et al. (2012), further described the use of cardiac troponin I to identify the presence 
of cardiac ischaemia within the specific context of the emergency department. Their study 
described the high sensitivity and specificity in this context and went on to discuss the 
relationship between clinical signs, ECG and the use of biomarkers. (31) Kemper et al (2017), 
further find support for the use of Troponin I in the emergency setting. (34) Thygesen et al 
and Amsterdam et al identify Troponin I as the preferred biomarker in diagnosing AMI. (5, 
35) 
In order to remain cost-effective, Troponin testing should not be delayed beyond a certain 
time frame, allowing appropriate, timeous therapeutic intervention and avoiding delay to 
reperfusion of cardiac myocytes and prolonged stay in ICU. (36) When Troponin I testing is 
used, it should be done early enough to allow for appropriately timed intervention.  
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Troponin Testing in the South African Context 
South African clinicians have, until recently, still been using a combination of older cardiac 
enzymes, according to Bellhudder (2012), which reduces cost-effectiveness and potentially 
contributes to misdiagnosis. (37)  Following a South African review in the same year, Troponin 
I has become accepted as standard of care. (38, 39) A study by Beukes et al (2018), indicates 
that initial and serial cardiac troponins are less readily accessible in Lower Middle Income 
Countries compared to High Income Countries. (40) 
 
The HEART guidelines have become integral to the South African acute cardiac ischaemia 
decision matrix. South Africa’s local clinical guidance resource, the Essential Medical 
Guidance, has incorporated the HEART score in its protocols since 2017, as illustrated below. 
(41) 
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Figure 1: The Clinical Decision Pathway (41) 
 
Note: Reprinted from Acute Coronary Syndromes, by EMCT (2017), retrieved from 
https://emguidance.com/guidelines by EMGuidance 
Troponin I is a quick, useful, easy to perform, but expensive resource.  As an observational 
study our study describe how Troponin I tests are used at a typical public setting; describing 
inconsistencies in the application of clinical resources and judgement. It should also highlight 
associations between the result and other quality and application measures, i.e. time to 
testing and symptoms prompting testing.  This would provide information regarding local 
testing thresholds and perceived risk that could be addressed from an educational and cost-
savings potential. 
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Risk assessment in acute coronary syndrome: Clinical Decision Rules 
By integrating history and clinical signs and symptoms, with characteristic ECG changes and 
the elevation of Troponin I, clinicians can further enhance the correct identification of cardiac 
ischaemia. This strategy requires that the using clinician follow a set standard of steps in 
order to risk stratify each patient’s likelihood of having had an ischaemic event. Clinical 
Decision Rules are tools that doctors may use in order to facilitate bedside clinical decisions 
and therapeutic interventions. 
Clinical Decision Rules may consist of a collection of signs and symptoms, patient-related 
demographic factors, bedside or laboratory tests or imaging and history. These collections of 
data need to be validated and show consistency in clinical practise, and require ease of use. 
Chang et al (2017) support the use of Clinical Decision Rules in addition to Troponin. Other 
studies which looked specifically at Clinical Decision Rules include Long et al (2017), which 
describes the HEART Score and pathway. (41, 42) Of the Clinical Decision Rules developed 
and tested, The HEART Score consistently performs the best. Similar tools such as the 
Thrombolysis in Myocardial Infarction (TIMI) and modified TIMI were found to be unable to 
classify patients into discrete groups, while the Global Registry of Acute Coronary Events 
(GRACE) Score was not designed to assess undifferentiated chest pain. (43, 44, 45)  
The HEART score consists of the following factors: History, ECG changes, Age of the patient, 
Risk factors and the level of Troponin. Points are allocated based on the nature of each 
factor: History, for example, would need to differentiate between non-specific, specific and 
highly suspicious for a myocardial infarction. Troponin results are allocated points based on 
whether they are negative, equivocal, or positive. These factors allow patients to be 
stratified according to their risk in the context of undifferentiated chest pain, and patients 
at a higher risk of a major adverse cardiac event (MACE) within the next 6 weeks to be 
identified. MACE events may include cardiovascular death, myocardial infarction, stroke, or 
non-coronary artery bypass graft-related major bleeding. 
 
Interpretation of Troponin Testing 
In the setting of a suspected AMI, ECG changes may suggest a STEMI or show features of 
NSTEMI. In the case of NSTEMI, Serial Troponins can be performed, with a repeat at 3-6 
hours. If the Troponin continues to be negative, the treating doctor may then use the HEART 
Score to risk stratify the patient into High, Intermediate, or Low Risk. Each risk level requires 
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a different action. High Risk patients are admitted, and cardiology referral is considered. 
Intermediate Risk patients May be admitted with a repeat Troponin done at 12 hours. Low 
Risk patients may be discharged. 
 
Risks of Over Testing 
We have explained how Troponin tests may be raised in conditions other than AMI, which 
has the potential to complicate the final treatment pathway. Unnecessary use of the 
Troponin test can be harmful and may lead to incorrect clinical diagnosis as well as costly 
and invasive investigations, such as angiography, which carries its own inherent risks. Further 
problems include prolonged hospital stay and waste of financial resources – especially of 
concern in this resource context. (46, 47, 48) 
 
Conclusion 
Diagnostic tests are required to aid the clinician in identifying patients at risk of MI, make a 
timeous diagnosis which allows for appropriate intervention and avoid missing patients who 
present atypically, but are at risk of cardiac ischaemia. We discussed the Troponin I test and 
its use as the primary cardiac enzyme, rather than other less sensitive or specific markers, 
appears to be well justified. We also discussed the role of the clinical decision-making 
guidelines and motivation is made for the use of the HEART guideline both internationally 
and locally.  
There appears to be a paucity of data describing how Troponin I tests are used in the broader 
South African context and in the Western Cape and Cape Town.  It is possible that the tests 
can be more judiciously applied, providing a cost-wise solution, without affecting safety and 
quality.  This links in with the aim of our study in the next chapter which is to describe the 
use of the relatively expensive Troponin I test within a local secondary level hospital. 
Understanding how this test is used in this clinical setting may provide guidance on its 
rational use in the Western Cape.  
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Abstract 
Introduction 
Troponin I tests have been shown to be accurate and are relied upon to assist in making 
critical decisions regarding patient care in patients presenting with chest pain. The tests are 
expensive, however, and so their rational use becomes extremely important in a budget-
constrained public health sector. The aim of this study was to describe how Troponin I tests 
are used throughout Victoria Hospital, by a range of requesting clinicians, working in different 
specialties. 
Methods 
A cross-sectional, prospective design was employed, using multiple data sources.  We 
collected a consecutive sample over a three-month period from Victoria hospital’s 
Emergency Centre using a dedicated data collection tool connected to use of the point-of-
care troponin I test. We supplemented this prospective sample with outcome data, using the 
hospital’s electronic admission record.  
Results 
Three hundred and sixteen patient entries were included in the final results. The majority of 
Troponin tests were negative (70%). Discharge directly from Emergency Centre was 10% in 
Troponin I positive patients, 37,5% in Equivocal Troponin patients, and 65% in Troponin 
negative patients. Furthermore, patients were twice as likely to be transferred to a tertiary 
facility if their Troponin was positive (24%), compared to equivocal (10.4%) or negative (12%). 
Discussion 
Chest pain was the most common presenting complaint, with Acute Coronary Syndrome 
being the most common working diagnosis. The clinical management of patients varied 
considerably when comparing their Troponin I result. Troponin I appears to be used as an 
effective rule-out tool in the decision-making pathway.  
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Introduction 
The sensitivity of Troponin I is estimated at >99% if taken between 3-6 hours from onset of 
injury, while the specificity is estimated at 80-85%.(1,2) This means that the test has a high 
likelihood of detecting cardiac myocyte damage, but that other conditions may cause the 
result to be elevated, resulting in a fairly high number of false positives.(2) Its high sensitivity 
also allows myocardial damage to be excluded with confidence if negative.(3)  
The cost of each Troponin I test ranges between ZAR 95.00 to ZAR 115.00, which is expensive 
for a single use test in a low- to middle-income setting. The machines used to interpret the 
test, the routine maintenance, and the requirement for Troponin I to be stored in a 
refrigerator all add to this cost.(4) Although its sensitivity is useful from an acute care 
perspective the relatively high cost compared to other commonly used tests is important 
from a local health economics context.(5)   Inappropriate use of Troponin and the 
misinterpretation of a false positive result can lead to further unnecessary testing later, 
including stress echocardiography, cardiac catheterisation and percutaneous 
intervention.(6) 
The aim of this study was to describe how Troponin I tests are used throughout Victoria 
Hospital, by a variety of requesting clinicians, across various levels of seniority and training 
and working in a range of specialties and areas within the hospital, in terms of indication, test 
finding (positive or negative), working diagnosis and outcome. 
 
Materials and Methods 
Study Design: 
A prospective, cross-sectional design was used, including multiple data sources.   
Characteristics of the Study Population: 
Victoria Hospital is a district level hospital, in Wynberg, Cape Town. It has 181 ward beds, 3 
day ward beds and an overnight ward. The available specialties include Surgery and 
Medicine, Emergency Medicine, Paediatrics, Psychiatry, Orthopaedics, Palliative Care and 
Auxiliary services. The hospital has a High Care Unit. Victoria hospital operates in the South 
Peninsula Health District of the Metro Region.  The Emergency Centre (EC) sees 47,000 
patients annually, while Victoria Hospital sees 83,950 annually. 
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We tracked the use of the Alere Triage Troponin I for this study as supplied by the local 
laboratory.  This assay is situated in the EC of Victoria hospital and has to be used here.  The 
user protocol requires that all hospital areas should have access to the assay via the EC. 
Presently, only clinicians have access to use of the assay, and testing is controlled through 
the EC.  Given the cost of the test, quality control and record keeping, clinicians have to 
complete a register when making use of the test.  The register includes patient location, 
indication for testing, working diagnosis and the result of the test. Further formal Troponin 
testing requires samples to be sent off-site to a tertiary hospital laboratory, 11km away.   
We estimated that the EC assay is used for approximately 50 patients over a 30-day period.  
As it was unclear exactly how the data would present following analysis, and due to the lack 
of local research on user workflow in troponin testing, we did not attempt a power 
calculation.  Instead we decided to collect a convenience sample over a three-month period. 
Recruitment and Enrolment: 
Data were collected from multiple sources.  We prospectively collected a consecutive sample 
of troponin testing over the study period using a dedicated data collection tool.  Essentially 
this data collection tool replaced the troponin I test register over the study period.  It 
captured all the information previously included with a few additional variables added for 
study purposes.  To reduce confusion, a hard copy register similar to the register used outside 
of the study was used.  A sample page from the register is provided in Appendix A.  We 
supplemented this sample with outcome data (discharge from Victoria EC, discharge from 
Victoria Hospital, transfer to tertiary centre, or death at Victoria Hospital or EC) using the 
hospital’s electronic admission record by matching the patient identifier (hospital number) 
from the register to the admission records. Missing data fields (outcome, patient age, patient 
gender and hospital area) in the hospital’s electronic admission record prompted a review of 
the clinical record of the relevant patient for the missing data points.  The variables collected 
from the register are listed in Table 1 (second column).  We excluded patients in which a full 
data set could not be obtained.  We accepted the following missing variables: patient age, 
gender and hospital area where the patient was situated.  Any other missing variables 
resulted in an unusable entry with exclusion of the patient.  Figure 1 describes the data 
collection strategy.   
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Table 1.  Variables collected for the sample 
Variables from register Variables from hospital electronic 
admission record and clinical record 
1. Hospital number 
2. Patient age 
3. Patient gender 
4. Hospital area where patient situated 
5. Clinician rank: consultant, medical 
officer, specialist trainee, community 
service medical officer, intern 
6. Primary indication for performing the 
test from the following:  
 chest pain,  
 other pain suggestive of ACS 
(arm(s), neck, back, abdomen),  
 shortness of breath,  
 observed ECG abnormalities 
associated with ACS 
7. Other indication (optional/ specified) 
8. Time of onset of symptoms 
9. Working diagnosis (specified) 
10. Troponin I result 
1. Outcome: discharge from Victoria EC, 
discharge from Victoria Hospital, 
transfer to tertiary centre, or death at 
Victoria Hospital/ EC 
2. Outcome: date outcome was achieved 
3. (Patient age) 
4. (Patient gender) 
5. (Hospital area where patient was 
situated during admission) 
EC, emergency centre; ACS, acute coronary syndrome; ECG, electrocardiogram; Variables 
in parenthesis indicate that variable will be supplemented only if not collected in the 
prospective register 
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Figure 2. Data collection strategy 
 
 
* Using Microsoft Excel 
** Hospital number 
 
Data Analysis: 
Data was captured in an Excel spreadsheet (Microsoft Office, Redmond, USA) which was also 
used to conduct the analysis.  Descriptive statistics were applied to the sample as follow: 
categorical variables, such as outcome, were described using proportions.  Where applicable, 
data were described using histograms and charts. We specifically looked for associations 
between troponin test results, indications for testing, onset of symptoms, working diagnosis 
and outcome.  For outcome, we also described the proportion of patients who reached an 
outcome within 48 hours of troponin testing.   
The study was approved by the Human Research Ethics Committee of the University of Cape 
Town, Reference Number: 737/2017. 
 
Results 
A total of 356 samples were collected, of which 40 were excluded due to incomplete entries, 
illegible entries and missing variables. 
  
Obtain 
initial 
sample 
from 
register
Record 
required 
data 
points in 
electronic 
format*
Obtain 
outcome 
data from 
hospital 
electronic 
database
Remove 
identifiers 
**
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Table 2. Patient Demographics and Baseline Characteristics 
Patient: Troponin 
Positive 
(49/16%) 
Troponin 
Equivocal 
(48/15%) 
Troponin 
Negative 
(219/69%) 
Total 
(316/100%) 
Sex 
     Men 
 
21/43% 
 
22/46% 
 
102/47% 
 
145/46% 
Sex 
      Women 
 
28/57% 
 
26/54% 
 
117/53% 
 
171/54% 
Age 
     Median 
     Range 
 
70 
27-83 
 
59 
40-83 
 
54 
25-94 
 
60 
25-94 
Hospital Area 
     EC 
     Other 
 
48/15.3% 
1/2% 
 
48/15.3% 
0/0% 
 
217/69.3% 
2/0.8% 
 
313/99% 
3/0.9% 
Outcome 
Transfer to Tertiary 
Discharge from EC 
Discharge from Hospital 
Death 
 
12/25% 
5/10% 
32/65% 
0/0% 
 
18/38% 
5/10% 
23/48% 
2/4% 
 
29/13% 
129/59% 
59/27% 
2/1% 
 
59/19% 
139/44% 
114/36% 
4/1% 
 
Clinicians requesting the troponin test consisted of 252/80% medical officers, 38/12% 
specialist trainees and 25/8% consultants.  
The test was performed by 167/53% medical officers, 111/35% interns, 25/8% specialist 
trainees and 13/4% consultants.  
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Chest pain was the most common primary indication for performing the test 218/69%, 
followed by ECG abnormalities associated with ACS 94/30%, shortness of breath 84/27%, 
other clinical features of ACS 42/13%, and other types of pain (described by pain radiating to 
the arm, neck or back, or abdominal pain) 37/12%. Many clinicians included more than one 
type of indication on the data sheet – this is described in limitations. 
The amount of time passed between the first onset of symptoms and the test being 
performed was described by the area in which the testing took place. The time in hours for 
Troponin testing in all areas was 9.37(±5.96), time for testing done in the EC was 9.03(±5.2) 
and time for Troponin testing done outside of the EC was 35(±4.5). 
Of patients with positive Troponin I tests, 65% were finally discharged from hospital, meaning 
that they were admitted under another specialty, such as Internal Medicine, and discharged 
once their treatment had been completed there. Further testing and interventions would 
then be carried out, including confirmation of a final diagnosis, but this did not form part of 
the study and is not commented on. 
 
Figure 3. Troponin test results with indications and outcomes 
Troponin 
result 
Working Diagnosis Reason for Test Outcome 
Positive 
49 (16%) 
   
Equivocal 
48 (15%) 
   
    
30
%
70
%
56
%14
%
18
%
12% 10%
65
%
25
%
40
%
60
%
47
%
28
%
15
%
10%
38
%
48
%
10%
4%
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Negative 
219 (69%) 
   
Legend: 
 ACS 
 Non-ACS 
  ECG abnormalities 
  Shortness of breath 
  Chest pain 
  Atypical / Other 
 Discharged from 
hospital 
  Transferred to tertiary 
care 
  Discharged from EC 
  death 
 
Discussion 
The primary indication or clinical presenting complaint spurring the use of Troponin I testing 
was chest pain. Shortness of breath, ECG Changes and other ACS symptoms made up the bulk 
of the rest of the tests, as may be expected in the multimodal pathway used to diagnose 
ischemia. (7) In the presence of chest pain, and following the Clinical Decision Pathway in use 
in the Western Cape Troponin is extremely useful in ruling out the presence of ischemia when 
used appropriately. (8) Limitations on indications are discussed in the Limitations section. 
Most of the Troponin tests performed were used for appropriate indications. There were, 
however, a large number (50) of working diagnoses for which Troponin testing would not 
have been indicated. These included diagnoses such as schizophrenia, diabetes, asthma 
exacerbation or similar.  Inappropriate use of Troponin I tests are a potential source of 
wasted resources and can lead to further unnecessary testing later, including stress ECG, 
cardiac catheterisation and percutaneous intervention. (6) 
Where Troponin test results were positive, however, the majority of working diagnoses were 
appropriate. There were three tests done with positive results but no indication: two for 
gastritis, and one for pneumonia. Serial testing was done in a small amount of cases, which 
can be appropriate in excluding ischemia by comparing levels over time, or when levels are 
equivocal.  
19
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%
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%
12
%
7%
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%
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%
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%
1%
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Troponin I is able to rule out the presence of an ischemic event by way of its absence when 
used in the appropriate time frame and this study looked at the duration of time passed 
between symptom onset and Troponin testing. The time taken between the onset of 
symptoms and performing the troponin tests appeared to be quite long, with a mean time of 
11 hours in EC. Although this could be beneficial in the context of ensuring a positive Troponin 
result, in the presence of ischaemia, it is detrimental in terms of patient treatment and 
addressing the presence of ischemia. Delayed diagnosis and intervention has been shown to 
result in prolonged stays in ICU. (9,10) 
There may be various factors responsible for this, presumably partly related to accessing 
health care facilities and partly to waiting times upon arrival in the EC. Access issues may 
include lack of means to contact an ambulance, lack of transport to get to hospital, long 
waiting times when waiting for an ambulance, long waiting times to be seen in the EC due to 
high volume of patients, despite the triage system being used effectively.  
Time taken to testing outside of EC was higher with a mean time of 35 hours.  It is not clear 
what the reason for this delay was, but may include new symptoms, delay to clinical 
suspicion, or clinical error. These were initial tests, belonging to patients who had not had a 
Troponin I before admission to their ward, either form EC or via transfer. The register was 
able to track repeat Troponins done via EC, but not those done through the National Health 
Laboratory Service. 
The outcomes and disposition vary significantly for each of the Troponin result categories. 
Possible outcomes listed in the data collection tool included: discharge from Victoria EC, 
discharge from Victoria Hospital, transfer to tertiary centre, or death at Victoria Hospital/ EC. 
Where the test was positive, patients were more likely to be admitted to hospital and 
discharged later, or be transferred to a tertiary facility. There is a significant proportion of 
patients with positive Troponins who were entered as discharged from Victoria EC – it is 
unclear whether this is a problem related to the options provided by the form itself, which 
may have led to misinterpretation by the using clinician or whether the limited disposition 
outcomes listed on the Clinicom are a contributing factor. Patients with negative results were 
far more likely to be discharged directly from the EC. It is interesting to note that of the deaths 
recorded in this study, none had positive Troponins. 
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Most Troponin tests were requested and performed by Emergency Medicine, with Internal 
Medicine requesting ten tests. Patients for whom the tests were performed were almost 
exclusively located in the Emergency Centre. High Care, Medical and Overnight wards each 
had one patient for whom a test was ordered. It is possible that a higher number of other 
specialties may request troponin I tests, but that the patients are still located in the EC, due 
to long waiting times to access ward beds. It should be noted that Internal Medicine sends 
an additional non-urgent Troponin specimen for laboratory testing, which may influence 
their use of the test. 
The majority of Troponin I tests were both requested and performed by medical officers, 
which make up the bulk of the employees in the Emergency Centre at Victoria Hospital. In 
cases where Consultants requested the Troponin tests, medical officers were also the most 
likely to perform them. These findings are not unexpected. It is possible that consultants 
should perhaps be more involved in the decision to perform tests, as a cost-saving measure. 
 
Limitations: 
The indications provided as options on the data collection tool, distributed by the researcher, 
allowed for the options of chest pain, other pain which may be associated with ACS such as 
arm, neck, back or abdominal pain, shortness of breath and ECG abnormalities associated 
with ACS. The user was able to decide between these options. Many users entered more than 
one indication on their data sheet – which makes identifying the primary indication 
impossible. 
There are further problems that arise with the data collection tool. Although it is assumed 
that the user has a knowledge of nuances in the complain of pain in ACS, the sheet does not 
provide any further explanation. It relies on the user’s discretion. If there were other subtler 
clinical signs present, which prompted the decision to perform a Troponin test, that did not 
clearly fit into any of the four options listed, the user would be forced to make a choice which 
may not entirely be explained by one of the four options listed.  
The data collection tool was not validated – it was not trialled before use to check 
appropriateness and understanding. Furthermore, it does not clarify what is meant by ECG 
abnormalities associated with ACS. It is not clear if there may have been a problem with the 
design of the form, as the working diagnosis was stated. 
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It is possible that a higher number of other specialties may request troponin I tests, but that 
the patients are still located in the EC, due to long waiting times to access ward beds. The 
register did not specify that patients should clearly be under another specialty’s care – so it 
is not possible to clarify this. 
Medical records do not indicate whether clinical support tools such as HEART score were 
used to guide care, though this is a guideline in place at present. ECG findings were not 
documented, which could have been useful to report on, as the HEART score uses 
normal/nonspecific repolarization abnormalities/significant ST deviation. 
 
Conclusion: 
The aim of this study was to describe the use of the relatively expensive, but essential, 
Troponin I test within Victoria Hospital. Understanding how these tests are used in the clinical 
setting can provide guidance on their rational use in the Western Cape, a relatively resource-
limited setting. This study described the use of Troponins by user seniority and training, 
department, indications for use, as well as final disposition. 
We noted that inappropriate use of the Troponin test decreased as the using clinician’s 
training and seniority increased. We showed increased waiting times for Troponin testing 
and suggested reasons for this, including possible causes of reduced access. We noted the 
inappropriate use of Troponin I based on presenting complaints and differential diagnosis – 
allowing for recommendations to be made.  
Major limitations include the use of the data collection tool, which was not validated before 
use. This may have contributed to user error.  
 
Suggestions for further research: 
Further research should be directed towards attempting to clarify treatment outcomes, and 
perhaps could further explore the reasons for users’ knowledge or interpretations of testing 
indications. The findings could also be compared to other similar hospitals in the region, 
which would enhance the strength of any recommendation.  
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Important limitations include a lack of data about clinicians’ use of a clinical decision tool, 
their interpretation of Troponin I results and how those influenced their care including 
further testing and interventions. Further limitations include a lack of data on the final 
diagnosis of MI, how transfer and referral decisions were made and outcomes of transferred 
patients. 
A mixed methods evaluation that integrates provider insights about how they decide to order 
troponins, whether cost factors into ordering decisions, and how they incorporate results 
into their management would be another informative follow-up study. 
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Part C. Addenda 
A. Relevant journal Instructions to Authors  
The relevant journal instructions for authors can be found at the following URL:  
http://www.journals.ac.za/index.php/SAHJ/article/view/1878  
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B. Data collection tool 
Patient sticker 
(if no sticker, please provide the following) 
Name: 
Hospital number: 
 
 
Surname: 
Date of birth 
Date now: 
 
Time now: 
Patient Location 
(e.g. EC, medical ward (specify which), 
theatre, etc.) 
 
 
 
Requesting clinician rank Working diagnosis? 
□ Consultant 
□ Specialist trainee 
□ medical officer 
□ Intern 
 
□ Community service medical officer 
Person performing test Reason for Test (Mark ALL that apply) 
□ Chest pain,  
□ Other pain suggestive of ACS (arm(s), 
neck, back, abdomen) 
□ Shortness of breath,  
□ ECG abnormalities associated with 
ACS 
□ Other (specify in box below) 
□ I am the requesting clinician (if not, please 
indicate below) 
□ Consultant 
□ Specialist trainee 
□ medical officer 
□ Intern 
□ Community service medical officer 
Specialty 
□ Emergency medicine Time of onset of symptoms? 
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□ Internal medicine Date: 
□ Critical care 
□ Surgery 
□ Anaesthesia Time: 
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Part D. Proposal for Research: 
A descriptive study of the use of Troponin I testing at a Cape Town district hospital 
 
 Lead Investigator: Joshua Gibson, GBSJOS001 (University of Cape Town) 
 Supervisor (principal): Stevan R Bruijns (University of Cape Town) 
 Supervisor: Jacques Malan (Victoria Hospital) 
 
Abstract 
Introduction 
Troponin I tests have been shown to be accurate and are relied upon to assist in making 
critical decisions regarding patient care in patients presenting with chest pain. The tests are 
expensive, however, and so their rational use becomes extremely important in a budget-
constrained public health sector. With the recent imperative to limit costs wherever possible, 
it becomes very important to ensure both quality control and judicious use of an expensive 
resource.  
The aim of this study is to describe how Troponin I tests are used throughout Victoria 
Hospital, by a range of requesting clinicians, across various levels of seniority and training 
(consultant, medical officer, specialist trainee, community service medical officer, or intern), 
and working in a range of specialties including surgery, critical care, anaesthetics, internal 
medicine and emergency care in terms of indication, finding (positive or negative), working 
diagnosis and outcome. 
Methods 
A cross-sectional (across a data range), prospective (pre-determined) design will be used, 
using multiple data sources.  The troponin I assay is situated in the EC of the hospital.  All 
hospital departments must use the assay in the EC to perform a troponin test as a troponin 
test is not offered by the local laboratory.  We will prospectively collect a consecutive sample 
over a three-month period from Victoria hospital’s EC using a dedicated data collection tool 
that will be connected to use of the point-of-care troponin I test.  During the study period 
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this data collection tool will replace the existing troponin I test results register and will 
capture all the data points previously captured with an additional few specifically for study 
purposes.  Variables will include patient demographics, indications for test, working diagnosis 
and test result.  We will then supplement this prospective sample with outcome data, using 
the hospital’s electronic admission record (Clinicom). It is estimated that EC Troponin test 
are used for approximately fifty patients per 30-day period. A three-month data collection 
should yield approximately 150 entries. 
Ethics 
There are a number of benefits to describing the use of an expensive resource from a quality 
control perspective, but also from a cost reduction perspective (identifying waste, improving 
understanding of test indications, etc.).  The study will not affect work flow and should not 
inconvenience the clinical pathway any more than the existing register does.  Patient identity 
will be protected through judicious record keeping.  Although data will be collected 
prospectively performing consent would simply not be feasible, nor would it allow us to 
collect a reasonable sample with the resources available to the study team.   
 
Introduction 
Troponin is a protein present in cardiac and skeletal muscle that plays a role in muscle 
contraction.(1) Troponin I, a subunit of Troponin, is present only in myocardium.(2) During 
damage to myocytes, such as myocardial infarction, Troponin I is released into the blood – 
and can be used as a marker of cardiac cell death.(3) This distinction allows the clinician to 
distinguish between infarction and angina, in a patient with chest pain.(4)  
The sensitivity of Troponin I is estimated at >99% if taken between 3-6 hours from onset of 
injury, while the specificity is estimated at 80-85%.(5,6) This means that the test has a high 
likelihood of detecting cardiac myocyte damage, but that other conditions may cause the 
result to be elevated.(6) Its high sensitivity also allows myocardial damage to be excluded 
with confidence if negative.(7)  
The release of Troponin takes place during any form of myocyte damage – this means that 
the protein will present in patients who have sustained cardiac muscle damage by other 
means.(8) This includes chronic cardiac causes of myocyte damage, such as in heart failure, 
arrhythmias, and inflammatory conditions such as myocarditis or pericarditis, 
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cardiomyopathies or traumatic cardiac injury, such as contusion (9) Non-cardiac conditions, 
which cause cardiac myocyte damage by indirect means, can also cause raised Troponin I 
levels – such as sepsis, kidney disease, aortic aneurysm, COPD or central nervous system 
disorders such as subarachnoid haemorrhage.(4,10,11) Certain drugs and toxins may have 
the same effect. This is why Troponin I results need to be interpreted in the context of clinical 
history, physical examination and the electrocardiogram (ECG).(12) Serial testing which 
reveals a significant increase in Troponin I levels over time is the best indicator of the 
presence of infarction.(13)  
Troponin I tests are expensive.  The cost of each Troponin I test ranges between R95 – R115. 
The machines used to interpret the test, the routine maintenance and the requirement for 
Troponin I to be stored in a refrigerator, add to the cost.(14) Although its sensitivity is useful 
from an acute care perspective the relatively high cost compared to other commonly used 
tests is important from a local health economics context.(15)   Inappropriate use of Troponin 
and the misinterpretation of a false positive result can lead to further unnecessary testing 
later, including stress echocardiography, cardiac catheterisation and percutaneous 
intervention.(16) 
 
Aim 
The aim of this study is to describe how Troponin I tests are used throughout Victoria 
Hospital, by a range of requesting clinicians, across various levels of seniority and training 
(consultant, medical officer, specialist trainee, community service medical officer, or intern), 
and working in a range of specialties including surgery, critical care, anaesthetics, internal 
medicine and emergency care in terms of indication, finding (positive or negative), working 
diagnosis and outcome. It should be noted that Internal Medicine sends an additional non-
urgent Troponin specimen for laboratory testing, which may influence their use of the test. 
Troponin I is a quick, easy to perform, useful but expensive resource.  As an observational 
study this study should describe how Troponin I tests are used throughout Victoria Hospital; 
describing inconsistencies in the application of clinical resources and judgement. It should 
also highlight associations between the result and other quality and application measures, 
i.e. time to testing and symptoms prompting testing.  This would provide suggestions 
regarding local testing thresholds and perceived risk that could be addressed from an 
educational and cost-savings potential. 
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Objectives: 
Description of Troponin I test utilization throughout Victoria Hospital, by requesting clinicians 
in terms of: 
1. The hospital area where the patient requiring the test is situated (e.g. EC, specific 
ward, theatre, etc.) 
2. The primary indication for performing the test using any of the following pre-
specified symptoms or signs: chest pain, other pain suggestive of ACS (arm(s), 
neck, back, abdomen), shortness of breath, observed ECG abnormalities 
associated with ACS as well as the time of onset of symptoms 
3. The troponin I result (positive or negative) 
4. The recorded working diagnosis 
5. The outcome following test in terms of discharge from EC, discharge from 
hospital, transfer to tertiary centre, or death 
 
Methodology 
Study Design: 
A cross-sectional (across a data range), prospective (pre-determined) design will be used, 
using multiple data sources.   
Characteristics of the Study Population: 
Victoria Hospital is a district level hospital, in Wynberg, Cape Town. It has 181 ward beds, 3 
day ward beds and an overnight ward. The available specialties include Surgery and 
Medicine, Emergency Medicine, Paediatrics, Psychiatry, Orthopaedics, Palliative Care and 
Auxiliary services. The hospital has a High Care Unit. Victoria hospital operates in the South 
Peninsula Health District of the Metro Region.  The EC sees 47,000 patients annually, while 
Victoria Hospital sees 83,950 annually. 
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The troponin I assay is situated in the EC of the hospital.  All hospital departments must use 
the assay in the EC to perform a troponin test as a troponin test is not offered by the local 
laboratory.  Only clinicians have access to the assay and testing is directed through the EC 
staff.  Clinicians are not denied use of the assay, but given the cost of the test, quality control 
and to ensure a clinical record of use, users have to complete a register with patient details 
that includes patient location, indication for testing and working diagnosis, prior to using the 
test.  Users also have to record the result after completing the test. It is estimated that EC 
Troponin test are used for approximately fifty patients per 30 day period. A three month data 
collection should yield approximately 150 entries. 
Recruitment and Enrolment: 
Data will be collected from multiple data sources.  We will prospectively collect a consecutive 
sample for objectives one through four over a three month period from Victoria hospital’s EC 
using a dedicated data collection tool that will be connected to use of the point-of-care 
troponin I test.  During the study period this data collection tool will serve as the troponin I 
test results register and will capture all the data points previously captured with an additional 
few specifically for study purposes.  For this purpose, a dedicated hard copy register with 
additional variable fields included would be used.  The variables to be collected from the 
register are listed in Table 1 (first column) and a sample of the form is provided in Appendix 
A. Acceptable missing variables may include patient age, patient gender and hospital area 
where the patient is situated.  These will not result in exclusion of the data point. Any further 
missing variables will result in an unusable entry. 
We will then supplement this prospective sample with outcome data, using the hospital’s 
electronic admission record (Clinicom) by matching the patient identifier (hospital number) 
from the register to the admission records. Missing data fields (outcome, patient age, patient 
gender and hospital area) in the hospital’s electronic admission record may also prompt 
reviewing the physical clinical record of the relevant patient for the missing data points.  The 
variables to be collected from the register are listed in Table 1 (second column).  We will 
exclude patients in which a full data set cannot be obtained. 
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Table 1.  Variables to be collected for the sample 
Variables from register Variables from hospital electronic 
admission record and clinical record 
11. Hospital number 
12. Patient age 
13. Patient gender 
14. Hospital area where patient situated 
15. Clinician rank: consultant, medical 
officer, specialist trainee, community 
service medical officer, intern 
16. Primary indication for performing the 
test from the following:  
 chest pain,  
 other pain suggestive of ACS 
(arm(s), neck, back, 
abdomen),  
 shortness of breath,  
 observed ECG abnormalities 
associated with ACS 
17. Other indication (optional/ specified) 
18. Time of onset of symptoms 
19. Working diagnosis (specified) 
20. Troponin I result 
6. Outcome: discharge from Victoria 
EC, discharge from Victoria 
Hospital, transfer to tertiary centre, 
or death at Victoria Hospital/ EC 
7. Outcome: date outcome was 
achieved 
8. (Patient age) 
9. (Patient gender) 
10. (Hospital area where patient were 
situated during admission) 
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EC, emergency centre; ACS, acute coronary syndrome; ECG, electrocardiogram; Variables 
in parenthesis indicate that variable will be supplemented only if not collected in the 
prospective register 
 
Research Procedures and Data collection methods: 
Figure 1 describes the data collection strategy.  Initial data obtained from the register will 
include a hospital number, but no other patient identifiers (i.e. names, date of birth, 
addresses, phone numbers, etc.).  The hospital number will be required to link the datasets 
from the register with the outcome as recorded in the hospital’s electronic admission record. 
Data Analysis: 
Data will be captured in an Excel spreadsheet (Microsoft Office, Redmond, USA) which will 
also be used to conduct the analysis.  Descriptive statistics would be applied to the sample.  
Continuous data such as age will be described using the mean and standard deviation.  
Categorical variables such as outcome will be described using proportions.  Where applicable 
data will be described using histograms and charts.  Where appropriate, statistical tests will 
be performed between categorical variables to show the strength of associations. However, 
the study’s main strength is felt to be in the descriptive findings.  We will specifically look for 
associations between troponin test results, indications for testing, onset of symptoms, 
working diagnosis and outcome.  For outcome, we will also describe the proportion of 
patients who reached an outcome within 48 hours of troponin testing.  Additional testing is 
not planned but may be included depending on the findings. 
  
 
 
* Using Microsoft Excel 
Obtain 
initial 
sample 
from 
register
Record 
required 
data 
points in 
electronic 
format*
Obtain 
outcome 
data from 
hospital 
electronic 
database
Remove 
identifiers 
**
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** Hospital number 
Figure 1. Data collection strategy 
 
Data Safety and Monitoring: 
Although the folder number will be captured initially to match data sets, it will be removed 
from the data sample prior to analysis starting.  Data will be collected onto a password 
protected Excel document and stored on an access controlled computer in an access 
controlled office.  No hard copy data are to be collected and copies of the register will not be 
made.  Transfer of data between study team will be made using encrypted institution email 
only. 
 
Ethical Considerations: 
Guidance on rational use of an expensive test is one of the beneficial outcomes expected. 
However, better use of the troponin test may have patient level benefits as well (in terms of 
interpretation and correctly guiding care).  The study won’t affect the care pathway, but 
cannot reasonably be carried out if consent is required given the nature of the subject. 
Potential risks include: 
 Patient confidentiality is always important to maintain and in this study it will not 
be threatened.  Upon completion of data collection, and before data analysis, all 
personal identifying information will be removed from the data, ensuring that the 
information collected cannot be traced back to individual patients. 
 Staff resources of the studied institution should not be burdened, as the lead 
investigator is not employed at Victoria Hospital and all activities related to the 
study will be performed out of normal work hours. Study will not affect work flow 
and should not inconvenience clinicians in any way.  
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Potential Benefits: 
 By understanding how the Troponin I test is used in Victoria Hospital, this study 
could act to assist in improving the rational use of Troponins within not only the 
EC but the whole hospital. 
 This could lead to cost-saving in a financially strained setting. 
 This could also assist in developing education around the use of Troponin I within 
the hospital. 
Informed consent process 
We request a waiver of consent.  As described below the data is de-identified. Although data 
will be collected prospectively performing consent would simply not be feasible, nor would 
it allow us to collect a reasonable sample with the resources available to the study team, to 
achieve the desired objectives of the study.  We feel that we have made reasonable 
arrangements for data management.   
Privacy and confidentiality 
Individual patients or participants’ identities will be protected by de-identifying the data prior 
to analysis. Although the patients’ folder numbers will be collected initially this will only be 
in order to link records to obtain outcome data.  However, we would not include any of these 
in the final sample to be analysed.  As described, the only identifier collected (hospital 
number) will be removed after data collection and prior to analysis. 
Reimbursement for participation 
There is no reimbursement for participation 
Emergency care and insurance for research-related injuries 
There is no risk for research related injury 
 
Dissemination of Findings: 
It is expected that the findings could be published as a short report or full paper in an open 
access journal. We would also like to disseminate its findings by presenting it at a conference.  
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All stakeholders will have access to the findings and data of the study. This includes the 
Western Cape Government and Victoria Hospital and Emergency Centre Management. 
 
Project Timeline: 
EMDRC (full): 2 months 
Ethics (HREC): 2 months 
WCG Health application: 2 months 
Data collection: 3 months 
Data Analysis: 3-4 months 
Write-up: 2 months  
 
Budget: 
The costs of this study will be borne by the lead investigator. An estimated breakdown: 
Personnel Compensation  R0 
Principal Investigator R0  
Consulting Services  R0 
Statistical Services R0  
Travel  R500 
Transport and Travel R500  
Equipment and Furniture  R0 
Computer R0  
Other  R1400 
Telephone R200  
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Internet R200  
Ethics Committee fee R0  
Stationery R500  
Printing R500  
Total costs:  R1900 
 
Travel to and from Victoria Hospital, in order to collect data recorded in register. Telephone 
use will be limited to single cell phone use and internet data or home internet use. UCT 
MMed students are able to access one hour free statistics service. Stationery and printing 
will be required on an ongoing basis. 
Conclusion: 
The aim of this study is to describe the use of the relatively expensive Troponin I test within 
Victoria Hospital by determining which symptoms prompt testing, which departments utilise 
the tests, and correlating this with outcome and working diagnosis. Understanding how these 
tests are used in the clinical setting can provide guidance on their rational use in the Western 
Cape. 
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